Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Lease Of Life For Merck Serono Reject Cilengitide

Executive Summary

Basing a company around a high-profile failed drug candidate is not for the faint hearted, but that's exactly what Dr. John March is doing with Merck Serono reject cilengitide. Scrip asked him what it will take to turn the cilengitide story around.

You may also be interested in...



Merck KGaA's 1st in class brain cancer drug cilengitide flunks Ph III

Merck KGaA's investigational drug for glioblastoma, the first-in-class integrin inhibitor cilengitide, has failed to meet its primary endpoint in a 500-patient Phase III trial. Flagged by Datamonitor last year as a key hope for the German firm's future revenue growth, cilengitide has not been officially discontinued - a Phase II trial in a subset of patients is continuing with data expected this year - but the drug's prospects look dim.

UK Reimbursement Decisions Focus Mostly On Cancer

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.

Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts

While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.

Topics

UsernamePublicRestriction

Register

LL1133148

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel